Fig. 4.

Effect of the GPx4 inhibitor RSL3 in CCl4-treated mice or E47 cells with FUNDC1 deficiency. WT or FUNDC1^-/- mice were intraperitoneally injected with RSL3 (2.5 mg/kg) once a day for 10 days. E47 cells were transfected with scrambled or FUNDC1 siRNA for 48 hrs and were then treated DMSO or RSL3 (1 μM for 24 hrs) prior to exposure to CCl4 for 12 hrs. (a) Representative immunoblots of FUNDC1, SLC7A11 and GPx4 in E47 cells (Vinculin as the loading control); (b) Quantitated FUNDC1 level; (c) Quantitated SLC7A11 level; (d) Quantitated GPx4 level (n = 5–6/group); (e) Level of MDA (n = 5–6/group); (f) Ratio of GSH to GSSG (n = 6/group); (g) MTT assay of cell survival (n = 6/group); (h) Representative images of C11-BODIPY staining; (i) Quantified mean fluorescence intensity of C11-BODIPY images (n = 20/group); (j) Ratio of liver-to-body weight (n = 5–6/group); (k) Representative images of Sirius Red staining; (l) Quantified Fibrotic area of Sirus Red staining (n = 5–6 mice per group); (m) Level of plasma ALS and AST (n = 5–6/group); and (n) Quantified neutrophil number. Mean ± SEM (detailed statistical results shown in Table S4); Statistical significance was set at p < 0.05. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)